Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine

Journal of Gastroenterology

Volumn 42, Issue 5, 2007, Pages 368-374

  Hosaka, Tetsuya ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Saitoh, Satoshi ^a   Kobayashi, Masahiro ^a   Someya, Takashi ^a   Sezaki, Hitomi ^a   Akuta, Norio ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Adefovir dipivoxil; HBeAg seroconversion; Hepatitis B virus; Lamivudine resistant mutant

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFICACY; DRUG RESPONSE; FACTORIAL ANALYSIS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NORMAL VALUE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEROCONVERSION; VIRUS DETECTION; BLOOD; DRUG COMBINATION; DRUG EFFECT; GENETICS; HEPATITIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY;

ADENINE; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 34447516976     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-007-2008-1     Document Type: Article

References (35)

1. JL Dienstag ER Schiff TL Wright RP Perrillo HWL Hann Z Goodman 1998 Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 339 61-8 10.1056/NEJM199807093390201
2. SL Doong CH Tsia RF Schinazi DC Liotta YC Cheng 1991 Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′thiacytidine and related analogues Proc Natl Acad Sci USA 88 8495-9 1656445 10.1073/pnas.88.19.8495 1:CAS:528:DyaK3MXms12qurk%3D
3. YF Liaw NWY Leung TT Chang R Guan DI Tai KY Ng 2000 Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B Gastroenterology 119 172-80 10889166 10.1053/gast.2000.8559 1:CAS:528:DC%2BD3cXlsFGltLs%3D
4. JL Dienstage RD Goldin EJ Heathcote HW Hann M Woessner SL Stephenson 2003 Histological outcome during long-term lamivudine therapy Gastroenterology 124 105-17 10.1053/gast.2003.50013
5. Y Suzuki H Kumada K Ikeda K Chayama Y Arase S Saitoh 1999 Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection J Hepatol 30 743-8 10365796 10.1016/S0168-8278(99)80123-8 1:CAS:528:DyaK1MXjtlKntLw%3D
6. R Ling D Mutimer M Ahmed EH Boxall E Elias GM Dusheiko 1996 Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine Hepatology 3 711-3 10.1002/ hep.510240339
7. HG Nierters P Honkoop EB Haagsma RA De Man SW Schalm AD Osterhaus 1998 Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine therapy J Infect Dis 177 1382-5
8. GA Tipples MM Ma KP Fischer VG Bain NM Keneteman DL Tyrrell 1996 Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo Hepatology 3 714-7
9. S Nafa S Ahmed D Tavan C Pichouc F Breby L Stuyver 2000 Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B Hepatology 32 1078-88 11050059 10.1053/jhep.2000.19619 1:STN:280:DC%2BD3M%2FivFagsQ%3D%3D
10. F Suzuki Y Suzuki A Tsubota N Akuta T Someya M Kobayashi 2002 Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy J Hepatol 37 824-30 12445424 10.1016/ S0168-8278(02)00281-7 1:CAS:528:DC%2BD38XoslCjtbo%3D
11. J Balzarini L Naesens P Herdewijn I Rosenberg A Holy R Pouwels 1989 Marked in vivo antiretrovirus activity of 9-(2-phosphonyl-methoxyethyl)adenine, a selective anti-human immunodeficiency virus agent Proc Natl Acad Sci USA 86 332-6 2911579 10.1073/pnas.86.1.332 1:CAS:528:DyaL1MXit1GjsbY%3D
12. E De Clercq 1989 New acquisitions in the development of anti-HIV agents Antiviral Res 12 1-19 2574562 10.1016/0166-3542(89)90064-8 1:CAS:528:DyaL1MXls1Klt7w%3D
13. E De Clercq 1990 Therapeutic potential of phosphonylmethoxyalkylpirines and pyrimidines as antiviral agents Drug Exp Clin Res 16 319-26 1:CAS:528:DyaK3MXitl2ksr8%3D
14. JC Lin E De Clercq JS Pagano 1987 Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication Antimicrob Agents Chemother 31 1431-3 2823699 1:CAS:528:DyaL2sXlvFSnsL0%3D
15. K Xiong C Flores H Yang JJ Toole CS Gibbs 1998 Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro Hepatology 28 1669-73 9828233 10.1002/ hep.510280629 1:CAS:528:DyaK1cXotFSgt7Y%3D
16. RJC Gilson KB Chopra AM Newell IM Murray-Lyon MR Nelson SJ Rice 1999 A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection J Viral Hepatitis 6 387-95 10.1046/j.1365-2893.1999.00182.x 1:STN:280:DC%2BD3c%2FnsFagsQ%3D%3D
17. R Perrillo HW Hann D Mutimer B Willems N Leung WM Lee 2004 Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus Gastroenterology 126 81-90 14699490 10.1053/ j.gastro.2003.10.050 1:CAS:528:DC%2BD2cXhtFGntL0%3D
18. MG Peters HW Hann P Martin EJ Heathcote P Buggisch R Rubin 2004 Adefovir dipivoxil alone or in combination with in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 91-101 14699491 10.1053/j.gastro.2003.10.051 1:CAS:528:DC%2BD2cXhtFGntLo%3D
19. T Hosaka F Suzuki Y Suzuki S Saitoh M Kobayashi T Someya 2004 Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus Intervirology 47 362-9 15564749 10.1159/000080881 1:CAS:528:DC%2BD2cXhtVagsbfM
20. K Chayama Y Suzuki M Kobayashi M Kobayashi A Tsubota M Hashimoto 1998 Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild-type after cessation of therapy Hepatology 27 1711-6 9620347 10.1002/hep.510270634 1:CAS:528:DyaK1cXjvVCrs78%3D
21. S Usuda H Okamoto H Imawari K Baba F Tsuda Y Miyakawa 1999 Serological detection of hepatitis B virus genotype by ELIZA with monoclonal antibodies to type-specific epitopes in the preS2-region product J Virol Method 80 97-112 10.1016/S0166-0934(99)00039-7 1:CAS:528:DyaK1MXjsVSht7s%3D
22. JH Hoofnagle AM Di Bisceglie 1997 The treatment of chronic viral hepatitis N Engl J Med 336 347-56 9011789 10.1056/NEJM199701303360507 1:STN:280:ByiC2Mnit10%3D
23. RN Chien YF Liaw M Atkins for the Asian Hepatitis Lamivudine Trial Group 1999 Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B Hepatology 30 770-4 10462384 10.1002/ hep.510300313 1:CAS:528:DyaK1MXmtVSkt7Y%3D
24. NWY Leung CL Lai TT Chang R Guan CM Lee KY Ng on behalf of the Asia Hepatitis Lamivudine Study Group 2001 Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy Hepatology 33 1527-32 11391543 10.1053/jhep.2001.25084 1:CAS:528:DC%2BD3MXktlygtLc%3D
25. RP Perrillo CL Lai YF Liaw JL Dienstag ER Schiff SW Schalm 2002 Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B Hepatology 36 186-94 12085364 10.1053/jhep.2002.34294 1:CAS:528:DC%2BD38Xlslyqsr4%3D
26. R De Franchis A Hadengue G Lau D Lavanchy A Lok N McIntyre 2003 EASL international consensus conference on hepatitis B J Hepatol 39 Suppl 1 S3-25 14708673
27. YF Liaw N Leung R Guan GK Lau I Merican 2003 Asia-Pacific consensus statement on the management of chronic hepatitis B: An update J Gastroenterol Hepatol 18 239-45 12603522 10.1046/j.1440-1746.2003.03037.x
28. ASF Lok BJ McMahon 2004 Chronic hepatitis B: Update of recommendations Hepatology 39 857-61 14999707 10.1002/hep.20110
29. YF Liaw JJY Sung WC Chow G Farrell CZ Lee H Yuen Cirrhosis Asian Lamivuidne Multicentre Study Group 2004 Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 51 1521-31 10.1056/NEJMoa033364
30. A Matsumoto E Tanaka A Rokuhara K Kiyosawa H Kumada M Omata 2005 Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients Hepatol Res 32 173-84 16024289 10.1016/j.hepres.2005.02.006 1:CAS:528:DC%2BD2MXmvVCmsbo%3D
31. K Ikeda Y Arase M Kobayashi T Someya S Saitoh Y Suzuki 2003 Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis Intervirology 46 96-104 12684548 10.1159/000069744 1:CAS:528:DC%2BD3sXisleqtL0%3D
32. N Akuta F Suzuki Y Suzuki H Sezaki T Hosaka T Someya 2005 Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: A 8-year follow-up study J Med Virol 75 491-8 15714490 10.1002/jmv.20305 1:CAS:528:DC%2BD2MXivFSgtbY%3D
33. ASF Lok CL Lai N Leung GB Yao ZY Cui ER Schiff 2003 Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 1714-22 14724824 10.1053/j.gastro.2003.09.033 1:CAS:528:DC%2BD2cXhtVOrug%3D%3D
34. H Izzedine JS Hulot V Launay-Vacher P Marcellini SJ Hadziyannis G Currie Adefovir Dipivoxil International 437 Study Group 2004 Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies Kidney Int 66 1153-8 15327411 10.1111/j.1523-1755.2004.00866.x 1:CAS:528:DC%2BD2cXnvVCrtbw%3D
35. P Angus R Vaughan S Xiong H Yang W Delaney C Gibbs 2003 Resistance to adefovir dipivoxil therapy associated with selection of a novel mutation in the HBV polymerase Gastroenterology 125 292-7 12891527 10.1016/ S0016-5085(03)00939-9